Company intelligence / Profile preview

Phoilex

New York, New York, United Statesphoilex.com ↗

Ownership: Private
Development stage: Other

Overview

Phoilex’s flagship product, Active ReLeaf Spot Gel, is clinically proven to provide rapid relief from itching and inflammation associated with eczema, psoriasis, TSW, and sensitive skin. In a 4-week study, 90% of users reported relief from itchy skin for 4–12 hours; 74% saw significant reduction in flare-ups after 8 weeks. The product is steroid-free and dermatologist-approved.

Therapeutic areas: Dermatology
Modalities: Botanical blendPlant-based therapyNon-pharmacological therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Phoilex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phoilex.

Explore the full profile